(CGEM) Cullinan Oncology - Ratings and Ratios
Cancer Therapies, Autoimmune Disease Treatments, Monoclonal Antibodies, Small Molecules, Bispecific Antibodies
CGEM EPS (Earnings per Share)
CGEM Revenue
Description: CGEM Cullinan Oncology
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The companys pipeline includes several promising candidates, such as zipalertinib, a small molecule in Phase 3 trial for non-small cell lung cancer, and CLN-978, a T cell engager for treating systemic lupus erythematosus and rheumatoid arthritis.
From a clinical perspective, the progress of zipalertinib in Phase 3 trials is significant, as it indicates a potential breakthrough in treating non-small cell lung cancer. Additionally, CLN-978s potential in treating autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis could provide a new therapeutic option for patients. Key Performance Indicators (KPIs) to watch include the trial completion rates, patient response rates, and potential FDA approval timelines.
From a financial perspective, Cullinan Therapeutics has a market capitalization of $462.68M USD, with a forward P/E ratio of 6.30, indicating a relatively low valuation compared to its projected earnings. The companys return on equity (RoE) is -29.47, suggesting significant investment in research and development. KPIs to monitor include the companys cash burn rate, R&D expenses as a percentage of revenue, and potential milestone payments from partnerships.
The companys collaborations with Adimab, LLC and Taiho Pharmaceutical Co., Ltd are also noteworthy, as they provide access to new technologies and potential co-development opportunities. Key metrics to track include the progress of these collaborations, potential milestone payments, and the impact on the companys cash reserves.
Overall, Cullinan Therapeutics promising pipeline, collaborations, and relatively low valuation make it an interesting opportunity for investors. However, the high-risk nature of biopharmaceutical investments and the companys negative RoE require careful consideration of the potential risks and rewards.
Additional Sources for CGEM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CGEM Stock Overview
Market Cap in USD | 463m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2021-01-08 |
CGEM Stock Ratings
Growth Rating | -73.9 |
Fundamental | -60.0 |
Dividend Rating | 0.0 |
Rel. Strength | -48.1 |
Analysts | 4.89 of 5 |
Fair Price Momentum | 5.33 USD |
Fair Price DCF | - |
CGEM Dividends
Currently no dividends paidCGEM Growth Ratios
Growth Correlation 3m | 27.6% |
Growth Correlation 12m | -93.5% |
Growth Correlation 5y | -55.4% |
CAGR 5y | -25.87% |
CAGR/Max DD 5y | -0.30 |
Sharpe Ratio 12m | -0.44 |
Alpha | -68.11 |
Beta | 0.985 |
Volatility | 56.07% |
Current Volume | 146.7k |
Average Volume 20d | 312.1k |
As of July 06, 2025, the stock is trading at USD 7.81 with a total of 146,725 shares traded.
Over the past week, the price has changed by +0.64%, over one month by -13.89%, over three months by +5.40% and over the past year by -51.73%.
No, based on ValueRay´s Fundamental Analyses, Cullinan Oncology (NASDAQ:CGEM) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -60.00 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CGEM is around 5.33 USD . This means that CGEM is currently overvalued and has a potential downside of -31.75%.
Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.
- Strong Buy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, CGEM Cullinan Oncology will be worth about 6.3 in July 2026. The stock is currently trading at 7.81. This means that the stock has a potential downside of -19.97%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 26.9 | 244.2% |
Analysts Target Price | 26.9 | 244.2% |
ValueRay Target Price | 6.3 | -20% |